Journal
BRITISH MEDICAL BULLETIN
Volume 131, Issue 1, Pages 5-17Publisher
OXFORD UNIV PRESS
DOI: 10.1093/bmb/ldz031
Keywords
human cytomegalovirus; vaccines; antivirals; infection; latency
Categories
Funding
- British Medical Research Programme Grant [MR/S00081X/1]
- Wellcome Research Studentship Grant
- MRC [MR/S00081X/1] Funding Source: UKRI
Ask authors/readers for more resources
Background: Human cytomegalovirus (HCMV) is a threat to immunologically weak patients. HCMV cannot yet be eliminated with a vaccine, despite recent advances. Sources of data: Sources of data are recently published research papers and reviews about HCMV treatments. Areas of agreement: Current antivirals target the UL54 DNA polymerase and are limited by nephrotoxicity and viral resistance. Promisingly, letermovir targets the HCMV terminase complex and has been recently approved by the FDA and EMA. Areas of controversy: Should we screen newborns for HCMV, and use antivirals to treat sensorineural hearing loss after congenital HCMV infection? Growing points: Growing points are developing drugs against latently infected cells. In addition to small molecule inhibitors, a chemokine-based fusion toxin protein, F49A-FTP, has shown promise in killing both lytically and latently infected cells. Areas timely for developing research: We need to understand what immune responses are required to control HCMV, and how best to raise these immune responses with a vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available